Moreover, the in vitro and in vivo experiments showed that MIR4435-2HG plays a key role in glutamine metabolism remodeling and cancer development by promoting STAT1/GLS1 signal pathway, suggesting that targeting GLS1 by specific inhibitor CB-839 may be a promising therapeutic strategy for FH-deficient RCC treatment. This evidence concerns the gene STAT1 and renal cell carcinoma.